  |
 | Up a level |
Li, R.K. and Tokunaga, E. and Adamchuk, H. and Vladimirov, V. and Yanez, E. and Lee, K.S. and Bondarenko, I. and Vana, A. and Hilton, F. and Ishikawa, T. and Tajima, K. and Lipatov, O. (2022) Long‑Term Safety and Efectiveness of PF‑05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2‑Positive Metastatic Breast cancer: Updated Results of a Randomized, Double‑Blind Study. BioDrugs, 36. pp. 55-69. ISSN 1173-8804 (Print) 1179-190X (Online)
Zhang, Q. and Xu, B. and Zhang, Q. and Sun, T. and Li, W. and Teng, Y. and Hu, X. and Bondarenko, I. and Adamchuk, H. and Zhang, L. and Trukhin, D. and Wang, S. and Zheng, H. and Tong, Z. and Zhang, X. and Liu, E. and Jiang, W. and Liu, S. and Luk, A. (2018) Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab. Annals of Oncology, Vol.29 (Supp.9). ix16. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
